TLR7/8 ligand, R-848, inhibits IgE synthesis by acting directly on B lymphocytes

Scandinavian Journal of Immunology

Volumn 67, Issue 6, 2008, Pages 560-568

  Shen, E ^a   Lu, L ^b   Wu, C ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; B7 ANTIGEN; CD40 ANTIBODY; CD40 ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; LIGAND; MONOCLONAL ANTIBODY; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SPLEEN CELL; TH1 CELL;

EID: 43549113087     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02105.x     Document Type: Article

References (35)

1. 1 Strachan DP. Hay fever, hygiene, and household size. BMJ 1989 ; 299: 1259–60.
2. 2 Vercelli D. Mechanisms of the hygiene hypothesis–molecular and otherwise. Curr Opin Immunol 2006 ; 18: 733–7.
3. 3 Sel S, Wegmann M, Sel S et al. Immunomodulatory effects of viral TLR ligands on experimental asthma depend on the additive effects of IL‐12 and IL‐10. J Immunol 2007 ; 178: 7805–13.
4. 4 Jones T. Resiquimod 3M. Curr Opin Investig Drugs 2003 ; 4: 214–8.
5. 5 Hemmi H, Kaisho T, Takeuchi O et al. Small anti‐viral compounds activate immune cells via the TLR7 MyD88‐dependent signaling pathway. Nat Immunol 2002 ; 3: 196–200.
6. 6 Jurk M, Heil F, Vollmer J et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R‐848. Nat Immunol 2002 ; 3: 499.
7. 7 Bernstein DI, Harrison CJ, Tomai MA, Miller RL. Daily or weekly therapy with resiquimod (R‐848) reduces genital recurrences in herpes simplex virus‐infected guinea pigs during and after treatment. J Infect Dis 2001 ; 183: 844–9.
8. 8 Pockros PJ, Guyader D, Patton H et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo‐controlled, double‐blind phase IIa studies. J Hepatol 2007 ; 47: 174–82.
9. 9 Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon‐inducing imidazoquinolinamine. Cancer Res 1992 ; 52: 3528–33.
10. 10 Vasilakos JP, Smith RM, Gibson SJ et al. Adjuvant activities of immune response modifier R‐848: comparison with CpG ODN. Cell Immunol 2000 ; 204: 64–74.
11. 11 Wu JJ, Huang DB, Tyring SK. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res 2004 ; 64: 79–83.
12. 12 Wille‐Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV‐1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV‐1 Gag‐specific Th1 and CD8 + T cell responses. J Immunol 2005 ; 174: 7676–83.
13. 13 Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ. The immune response modifiers imiquimod and R‐848 are potent activators of B lymphocytes. Cell Immunol 2000 ; 203: 55–65.
14. 14 Bishop GA, Hsing Y, Hostager BS, Jalukar SV, Ramirez LM, Tomai MA. Molecular mechanisms of B lymphocyte activation by the immune response modifier R‐848. J Immunol 2000 ; 165: 5552–7.
15. 15 Bishop GA, Ramirez LM, Baccam M, Busch LK, Pederson LK, Tomai MA. The immune response modifier resiquimod mimics CD40‐induced B cell activation. Cell Immunol 2001 ; 208: 9–17.
16. 16 Kay AB. Allergy and allergic diseases. N Engl J Med 2001 ; 344: 30–7.
17. 17 Platts‐Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001 ; 64: S1–5.
18. 18 Ngoc PL, Gold DR, Tzianabos AO, Weiss ST, Celedon JC. Cytokines, allergy, and asthma. Curr Opin Allergy Clin Immunol 2005 ; 5: 161–6.
19. 19 Finkelman FD, Katona IM, Urban JF Jr et al. IL‐4 is required to generate and sustain in vivo IgE responses. J Immunol 1988 ; 141: 2335–41.
20. 20 Snapper CM, Peschel C, Paul WE. IFN‐gamma stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. J Immunol 1988 ; 140: 2121–7.
21. 21 Jabara HH, Fu SM, Geha RS, Vercelli D. CD40 and IgE: synergism between anti‐CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 1990 ; 172: 1861–4.
22. 22 Jeppson JD, Patel HR, Sakata N, Domenico J, Terada N, Gelfand EW. Requirement for dual signals by anti‐CD40 and IL‐4 for the induction of nuclear factor‐κB, IL‐6, and IgE in human B lymphocytes. J Immunol 1998 ; 161: 1738–42.
23. 23 Fujiwara H, Kikutani H, Suematsu S et al. The absence of IgE antibody‐mediated augmentation of immune responses in CD23‐deficient mice. Proc Natl Acad Sci USA 1994 ; 19: 6835–9.
24. 24 Yu P, Kosco‐Vilbois M, Richards M, Kohler G, Lamers MC. Negative feedback regulation of IgE synthesis by murine CD23. Nature 1994 ; 30: 753–36.
25. 25 Burlinson EL, Graber P, Bonnefoy JY, Ozanne BW, Cushley W. Soluble CD40 ligand induces expression of CD25 and CD23 in resting human tonsillar B lymphocytes. Eur J Immunol 1996 ; 26: 1069–73.
26. 26 Tangye SG, Hodgkin PD. Divide and conquer: the importance of cell division in regulating B‐cell responses. Immunology 2004 ; 112: 509–20.
27. 27 Wagner TL, Ahonen CL, Couture AM et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R‐848 and imiquimod. Cell Immunol 1999 ; 191: 10–9.
28. 28 Xu L, Rothman P. IFN‐γ represses ε germline transcription and subsequently down‐regulates switch recombination to ε. Int Immunol 1994 ; 6: 515–21.
29. 29 Kiniwa M, Gately M, Gubler U, Chizzonite R, Fargeas C, Delespesse G. Recombinant interleukin‐12 suppresses the synthesis of immunoglobulin E by interleukin‐4 stimulated human lymphocytes. J Clin Invest 1992 ; 90: 262–6.
30. 30 Gururajan M, Jacob J, Pulendran B. Toll‐like receptor expression and responsiveness of distinct murine splenic and mucosal B‐cell subsets. PLoS ONE 2007 ; 2: e863.
31. 31 Pasare C, Medzhitov R. Control of B‐cell responses by Toll‐like receptors. Nature 2005 ; 438: 364–8.
32. 32 Ruprecht CR, Lanzavecchia A. Toll‐like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006 ; 36: 810–6.
33. 33 Frotscher B, Anton K, Worm M. Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors. J Invest Dermatol 2002 ; 119: 1059–64.
34. 34 Peng Z, Wang H, Mao X, HayGlass KT, Simons FE. CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down‐regulate ongoing IgE responses in mice. Int Immunol 2001 ; 13: 3–11.
35. 35 Hasbold J, Lyons AB, Kehry MR, Hodgkin PD. Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL‐4. Eur J Immunol 1998 ; 28: 1040–51.